ROH-202 ophthalmic solution phase I clinical trial -Single and multiple dose study-

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051210197

Enrollment

Registered

2022-03-22

Start date

2022-03-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer

Interventions

Ophthalmic dose of ROH-202 or placebo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Japanese healthy adult male, >=20 and =18.5 and <25.0 of BMI

Exclusion criteria

Exclusion criteria: 1) Subject with a serious history of eye, brain, liver, kidney, heart, lung, gastrointestinal, hematological, endocrine, metabolic, or neurological 2) Subjects with current or with a history of drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
Safety, pharmacokinetics	—

Contacts

Public ContactTakashi Kitano

ROHTO Pharmaceutical Co., Ltd.

rohtocl@rohto.co.jp+81-6-6758-6925

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026